fda warning compounding semaglutide september 2025 Drug compounders sue over declaration ending Wegovy shortage FDA and Novo Nordisk Warned

peer review: 2 approved]

Sprint Nextel Corp

Risk factors for PBH include female sex, absence of preoperative diabetes mellitus, large postoperative weight loss, use of selective serotonin reuptake inhibitor or serotonin and noradrenaline reuptake inhibitor antidepressants, RYGB (compared with VSG), prior cholecystectomy 128 , and a history of symptoms potentially related to hypoglycaemia prior to surgery 122,129,130

Whats changing: First GLP-1 weight loss pill approved: Novo Nordisks oral Wegovy is expected to be widely available, with another pill from Eli Lilly likely later this year offering a needle-free option many patients prefer

Its normal to eat less in the first week or two without immediate weight loss

However, it is not known whether these effects can also be attributed to a direct action of GLP-1 RAs